UCB : Berenberg, Buy, raises its price target
In a research note, the analyst stresses that the group has enjoyed a solid start to the year after a transition phase which penalized both its financial performance and its stock market performance.
With four new product launches currently underway, the laboratory is now well on track to benefit from a future period of growth, he concludes.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.
Go to the original article.
Contact us to request a correction